Mankind Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Midcap 150 and 3.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board approved audited consolidated results for Q4 and FY25. FY25 revenue from operations rose to INR 12,207.44 crores (up about 19% from INR 10,260.44 crores in FY24), while net profit grew to INR 2,011.12 crores from INR 1,941.77 crores. Q4 FY25 revenue jumped to INR 3,079.37 crores but Q4 profit dipped to INR 424.65 crores from INR 476.59 crores a year ago, reflecting higher costs post the BSV acquisition. The board appointed M/s Amit Gupta & Associates as Secretarial Auditor for five years (subject to shareholder approval) and re-appointed M/s M.K. Kulshrestha & Associates as Cost Auditor for FY26; the joint statutory auditors (S.R. Batliboi & Co. LLP and Bhagi Bhardwaj Gaur & Co.) remain unchanged and issued an unmodified opinion. Other items include enhanced corporate guarantees for two subsidiaries and approval to incorporate a wholly owned subsidiary in Sri Lanka.
Despite strong full-year revenue growth driven by the BSV acquisition, the slight Q4 profit dip and ongoing income tax disputes (disallowances of ~INR 1,547 crores being appealed) may weigh on near-term sentiment, though the new subsidiary in Sri Lanka signals continued expansion. The change referenced in the headline is only the routine appointment of a new secretarial auditor; the statutory auditors are unchanged, so this is not a governance red flag.